A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic?
Returns on pharma R&D investment are at a nine-year low, and the cost of developing a drug has nearly doubled since 2010, according to Deloitte’s yearly assessment of the industry’s pip
Jacobio Pharma has reported the results of its pivotal Chinese study of KRAS G12C inhibitor glecirasib, with a safety profile that could differentiate it from other drugs
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.